Herpes simplex virus: Drug resistance and new treatment options using natural products (Review)

Molecular Medicine Reports

Volumn 1, Issue 5, 2008, Pages 611-616

  Mundinger, Tabea Anne ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti viral agents; Chemotherapy; Drug resistance; Herpes simplex virus; Natural products; Pharmacognosy

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BETULONIC ACID; CAFFEIC ACID; CALCIUM SPIRULAN; CARRAGEENAN; CIDOFOVIR; CINEOLE; CIS CAPSAICIN; CURCUMIN; EUGENOL; FK 3000; FLAVONE DERIVATIVE; FLAVONOID; FOSCARNET; GALACTOFUCAN; GALANGIN; ISOBORNEOL; KAEMPFEROL; MELIACINE; MORONIC ACID; NATURAL PRODUCT; PENCICLOVIR; PROPOLIS; RHAMNAN SULFATE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG STRUCTURE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; IC 50; IMMUNOCOMPROMISED PATIENT; IN VIVO STUDY; INCIDENCE; INFECTION RISK; LATENT VIRUS INFECTION; NONHUMAN; REVIEW; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; SKIN DEFECT; SPIRULINA PLATENSIS; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

HERPES; SIMPLEXVIRUS;

EID: 69449090458     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000001     Document Type: Review

References (54)

1. Nahmias AJ, Lee FK and Beckman-Nahmias S: Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis 69 (Suppl): 19-36, 1990. (Pubitemid 20333084)
2. Smith JS and Robinson NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186 (Suppl 1): 3-28, 2002.
3. Stevens JG: Latent herpes simplex virus and the nervous system. Curr Top Microbiol Immunol 70: 31-50, 1975.
4. Wheeler CE Jr: Pathogenesis of recurrent herpes simplex infections. J Invest Dermatol 65: 341-346, 1975.
5. Severson JL and Tyring SK: Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol 135: 1393-1397, 1999.
6. Thomas J and Rouse BT: Immunopathogenesis of herpetic ocular disease. Immunol Res 16: 375-386, 1997.
7. Xu F, Sternberg MR, Kottiri BJ, et al: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296: 964-973, 2006. (Pubitemid 44285373)
8. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA and Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73-83, 2006.
9. Wald A and Link K: Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185: 45-52, 2002. (Pubitemid 34043015)
10. Strick LB, Wald A and Celum C: Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 43: 347-356, 2006. (Pubitemid 44078908)
11. Elion GB, Furman PA, Fyfe JA, De Miranda P, Beauchamp L and Schaeffer HJ: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74: 5716-5720, 1977.
12. Boyd MR, Bacon TH, Sutton D and Cole M: Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 31: 1238-1242, 1987. (Pubitemid 17157607)
13. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM and Vere Hodge RA: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 36: 2747-2757, 1992.
14. Elion GB: Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol (Suppl 1): 2-6, 1993.
15. Ilsley DD, Lee SH, Miller WH and Kuchta RD: Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 34: 2504-2510, 1995.
16. Lowe DM, Alderton WK, Ellis MR, et al: Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpes-viruses. Antimicrob Agents Chemother 39: 1802-1808, 1995.
17. Chrisp P and Clissold SP: Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41: 104-129, 1991.
18. De Clercq E: Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh K Acad Geneeskd Belg 58: 19-49, 1996.
19. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC and Hitchcock MJ: Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 41: 197-202, 1992.
20. Boon RJ, Bacon TH, Robey HL, et al: Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey. J Antimicrob Chemother 46: 1051, 2000.
21. Christophers J, Clayton J, Craske J, et al: Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 42: 868-872, 1998. (Pubitemid 28216369)
22. Kost RG, Hill EL, Tigges M and Straus SE: Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 329: 1777-1782, 1993. (Pubitemid 23355551)
23. Swetter SM, Hill EL, Kern ER, et al: Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis 177: 543-550, 1998.
24. Field HJ: Herpes simplex virus antiviral drug resistance - current trends and future prospects. J Clin Virol 21: 261-269, 2001.
25. Gilbert C, Bestman-Smith J and Boivin G: Resistance of herpes-viruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 5: 88-114, 2002. (Pubitemid 35024271)
26. Blower S: Modelling the genital herpes epidemic. Herpes 11 (Suppl 3): 138A-146A, 2004.
27. Gaudreau A, Hill E, Balfour HH Jr, Erice A and Boivin G: Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 178: 297-303, 1998. (Pubitemid 28347909)
28. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M and Thouvenot D: Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 182: 290-293, 2000. (Pubitemid 30497816)
29. Greco A, Diaz JJ, Thouvenot D and Morfin F: Novel targets for the development of anti-herpes compounds. Infect Disord Drug Targets 7: 11-18, 2007. (Pubitemid 46488256)
30. Bourne KZ, Bourne N, Reising SF and Stanberry LR: Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Res 42: 219-226, 1999. (Pubitemid 29335909)
31. Dimitrova Z, Dimov B, Manolova N, Pancheva S, Ilieva D and Shishkov S: Antiherpes effect of Melissa officinalis L. extracts. Acta Microbiol Bulg 29: 65-72, 1993.
32. Chiang LC, Chiang W, Chang MY, Ng LT and Lin CC: Antiviral activity of Plantago major extracts and related compounds in vitro. Antiviral Res 55: 53-62, 2002. (Pubitemid 34655642)
33. Kutluay SB, Doroghazi J, Roemer ME and Triezenberg SJ: Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology 373: 239-247, 2008.
34. Benencia F and Courreges MC: In vitro and in vivo activity of eugenol on human herpesvirus. Phytother Res 14: 495-500, 2000.
35. Serkedjieva J and Manolova N: Plant polyphenolic complex inhibits the reproduction of influenza and herpes simplex viruses. Basic Life Sci 59: 705-715, 1992.
36. Bourne N, Bernstein DI and Stanberry LR: Civamide (ciscapsaicin) for treatment of primary or recurrent experimental genital herpes. Antimicrob Agents Chemother 43: 2685-2688, 1999. (Pubitemid 29519548)
37. Cheng HY, Lin TC, Ishimaru K, Yang CM, Wang KC and Lin CC: In vitro antiviral activity of prodelphinidin B-2 3,3′-di-O-gallate from Myrica rubra. Planta Med 69: 953-956, 2003.
38. Amoros M, Simoes CM, Girre L, Sauvager F and Cormier M: Synergistic effect of flavones and flavonols against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis. J Nat Prod 55: 1732-1740, 1992. (Pubitemid 23023259)
39. Lyu SY, Rhim JY and Park WB: Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch Pharm Res 28: 1293-1301, 2005. (Pubitemid 41781926)
40. Armaka M, Papanikolaou E, Sivropoulou A and Arsenakis M: Antiviral properties of isoborneol, a potent inhibitor of herpes simplex virus type 1. Antiviral Res 43: 79-92, 1999. (Pubitemid 29415655)
41. Kurokawa M, Basnet P, Ohsugi M, et al: Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo. J Pharmacol Exp Ther 289: 72-78, 1999.
42. Nawawi A, Nakamura N, Meselhy MR, et al: In vivo antiviral activity of Stephania cepharantha against herpes simplex virus type-1. Phytother Res 15: 497-500, 2001.
43. Alche LE, Barquero AA, Sanjuan NA and Coto CE: An antiviral principle present in a purified fraction from Melia azedarach L. leaf aqueous extract restrains herpes simplex virus type 1 propagation. Phytother Res 16: 348-352, 2002.
44. Alche LE, Berra A, Veloso MJ and Coto CE: Treatment with meliacine, a plant derived antiviral, prevents the development of herpetic stromal keratitis in mice. J Med Virol 61: 474-480, 2000. (Pubitemid 30450689)
45. Pifarre MP, Berra A, Coto CE and Alche LE: Therapeutic action of meliacine, a plant-derived antiviral, on HSV-induced ocular disease in mice. Exp Eye Res 75: 327-334, 2002. (Pubitemid 35216450)
46. Carlucci MJ, Ciancia M, Matulewicz MC, Cerezo AS and Damonte EB: Antiherpetic activity and mode of action of natural carrageenans of diverse structural types. Antiviral Res 43: 93-102, 1999. (Pubitemid 29415656)
47. Carlucci MJ, Scolaro LA and Damonte EB: Inhibitory action of natural carrageenans on Herpes simplex virus infection of mouse astrocytes. Chemotherapy 45: 429-436, 1999.
48. Talarico LB, Zibetti RG, Faria PC, et al: Anti-herpes simplex virus activity of sulfated galactans from the red seaweeds Gymnogongrus griffithsiae and Cryptonemia crenulata. Int J Biol Macromol 34: 63-71, 2004.
49. Pujol CA, Scolaro LA, Ciancia M, Matulewicz MC, Cerezo AS and Damonte EB: Antiviral activity of a carrageenan from Gigartina skottsbergii against intraperitoneal murine herpes simplex virus infection. Planta Med 72: 121-125, 2006.
50. Lee JB, Hayashi K, Hayashi T, Sankawa U and Maeda M: Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum. Planta Med 65: 439-441, 1999.
51. Ponce NM, Pujol CA, Damonte EB, Flores ML and Stortz CA: Fucoidans from the brown seaweed Adenocystis utricularis: extraction methods, antiviral activity and structural studies. Carbohydr Res 338: 153-165, 2003.
52. Thompson KD and Dragar C: Antiviral activity of Undaria pinnatifida against herpes simplex virus. Phytother Res 18: 551-555, 2004.
53. Hayashi K, Hayashi T and Kojima I: A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Res Hum Retroviruses 12: 1463-1471, 1996.
54. Lee JB, Srisomporn P, Hayashi K, Tanaka T, Sankawa U and Hayashi T: Effects of structural modification of calcium spirulan, a sulfated polysaccharide from Spirulina platensis, on antiviral activity. Chem Pharm Bull (Tokyo) 49: 108-110, 2001.